GUANGZHOU, China, April 17, 2025 /PRNewswire/ -- On April 15, the 137th Canton Fair opened in Guangzhou, attracting over 31,000 exhibitors and more than 60,000 overseas buyers attending in person. As a leader in electric two- and three-wheelers, TAILG has the largest booth in the industry, featuring 19 innovative models that captured international attention.
At the fair, TAILG showcases models including the Laser Armor Series, Feminine Series, high-speed electric motorcycles, cross-riders, and three-wheelers.
The Laser Armor Series, featuring a dual-headlamp mech design, captures attention with its striking mech aesthetics and cutting-edge technology. Notably, the F52 2025 model is equipped with the industry's first V6 flat-wire wheel hub motor, integrating new energy technology for stronger power and extended range.
The Feminine Series, represented by the R53, addresses female riders' daily mobility needs, while the step-through Series (T80PRO, T61L,T72L) offers long-range urban solutions. High-speed models S91PRO and S92PRO, with their mech-inspired aesthetics and exceptional performance, have gained recognition in international markets.
Visitors also experienced intelligent manufacturing and premium test-ride services at the Huizhou base.
On the opening day of the Canton Fair, the company secured key agreements and new orders, boosting its overseas expansion. From the delivery of the electric mobility project in Thailand to the base commissioning in Vietnam, from the office opening in Indonesia to its presence at EICMA 2024, TAILG has established seven global marketing centers, including benchmark markets in Southeast Asia like Vietnam and Indonesia. Facing global trade risks and opportunities, TAILG's international expansion is steadily progressing.
As a pioneer in long-range electric vehicles, TAILG remains committed to a technology-driven global strategy and the advancement of low-carbon mobility.
Since becoming the UNEP E-Mobility Partner in 2019, TAILG's international expansion has been highlighted by participation in the 2024 United Nations Climate Change Conference (COP29) and a letter of appreciation from the Ministry of Ecology and Environment, underscoring the company's influence in E-Mobility.
About TAILG
TAILG Group was established in Shenzhen, China in 2003. It's a group company integrating R&D, production, sales of electric two & three-wheelers, as well as the whole industry chain of sharing, charging and switching. TAILG has ten manufacturing bases worldwide with over 15 million units annually, and exports over 90 nations with more than 30,000 stores and served over 45 million consumers.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
TAILG Shines at the 137th Canton Fair with a Diverse Lineup of Electric Vehicles
AUCKLAND, New Zealand, May 2, 2025 /PRNewswire/ -- Soft tissue regeneration company, Aroa Biosurgery, is pleased to announce a milestone in clinical evidence.
There are now over 100 peer-reviewed studies describing the efficacy of the company's proprietary AROA ECM technology.
AROA's most recent publication was a large retrospective analysis of real-world evidence (RWE) from wound care centers in the US, assessing the efficacy of the company's Endoform NaturalTM product in treating venous leg ulcers (VLUs), in comparison to a leading reconstituted collagen dressing.
VLU's are open sores that are hard-to-heal because of impaired blood flow and can be very debilitating and painful. These types of wounds are difficult for clinicians to treat successfully. For example, only ~40% of VLUs can be healed after 3 months of treatment and there is a relatively high chance that these wounds will recur[1].
The peer-reviewed study, entitled "Clinical Efficacy of Ovine Forestomach Matrix and Collagen/Oxidized Regenerated Cellulose for the Treatment of Venous Leg Ulcers: A Retrospective Comparative Real-World Evidence Study" was published in the open access journal 'International Wound Journal in April 2025.
The study compared 470 VLU's that had been treated with Endoform Natural to 360 VLU's that had been treated with a reconstituted collagen product. The study used existing data from 223 wound care centers with minimal inclusion or exclusion criteria so that 'real-world' use of both products could be compared.
"There is a growing awareness of RWE studies to validate clinical performance" says Chief Scientific Officer, Dr. Barnaby May. "These types of studies enable much larger patient numbers to be compared versus traditional randomized controlled trials. Given that RWE studies use data from 'real-world' use of a treatment, the results can be more meaningful, especially in wound care where there is a high degree of variability in how wounds are cared for and patient factors."
The study found that VLUs treated with Endoform Natural healed up to ~ 8 weeks faster versus the comparator group, and the chances of the wound healing were significantly improved when Endoform Natural was used as part of treatment.
The striking difference in the healing outcomes demonstrate the potential for considerable cost reductions and improvements in patient quality of life, due to the significant improvements seen when VLUs were treated using Endoform Natural.
Dr. Gregory Bohn MD was part of the research team. "I was first introduced to Endoform in 2012 and started using the product to treat my own patients with VLUs. This new data validates what I have seen in my own practice managing VLUs with Endoform."
This is the second large retrospective RWE comparing Endoform Natural to a leading reconstituted collagen dressing. A previous study included the analysis of over 2,200 diabetic foot ulcers (DFUs) and also demonstrated significantly faster healing of DFUs using Endoform Natural[2].
The study is available online here.
[1] Kolluri R, Lugli M, Villalba L, Varcoe R, Maleti O, Gallardo F, et al. An estimate of the economic burden of venous leg ulcers associated with deep venous disease. Vasc Med. 2022;27(1):63-72.
[2] Bosque BA, Frampton C, Chaffin AE, Bohn GA, Woo K, DeLeonardis C, Lepow BD, Melin MM, Madu T, Dowling SG, May BCH. Retrospective real-world comparative effectiveness of ovine forestomach matrix and collagen/ORC in the treatment of diabetic foot ulcers. Int Wound J. 2022 May;19(4):741-753.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
AROA hits evidence milestone with real-world study validating the efficacy of Endoform in treating challenging venous leg ulcers.
